Taro Pharmaceuticals just announced that they have partnered with BioPlus as the exclusive dispenser of the new specialty generic medication deferiprone.

Deferiprone (the generic form of Ferriprox®) treats transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Thalassemia is a genetic-based group of blood disorders that can cause anemia due to changes in hemoglobin.

Although thalassemia syndromes are considered rare in the United States, they are still the most common autosomal recessive disorders. These syndromes affect an estimated 1 in 100,000 people. Even with treatment, these syndromes can be associated with the complication of iron overload, due to frequent blood transfusions.

If you’re looking for a generic iron chelator option for your patients with thalassemia syndromes, know that deferiprone is now here and available from BioPlus. Thank you, Taro Pharmaceuticals for choosing BioPlus as the exclusive distributor of this medication. And, as always, you can count on BioPlus for the specialty pharmacy medications your patients need.